TBC1D10C Inhibitors
TBC1D10C inhibitors represent a class of chemical compounds that specifically target the TBC1D10C protein, a member of the TBC (Tre-2/Bub2/Cdc16) domain family of proteins. These proteins are GTPase-activating proteins (GAPs) that regulate small GTPases, particularly those involved in intracellular trafficking and vesicle formation. The TBC1D10C protein functions by catalyzing the conversion of active GTP-bound small GTPases into their inactive GDP-bound forms, thus acting as a key regulator of various cellular processes, such as endocytosis, exocytosis, and membrane trafficking. Small GTPases, such as those in the Rab family, require tight regulation for proper intracellular vesicle trafficking, and TBC1D10C inhibitors interfere with this regulation, providing insight into the modulation of these fundamental cellular functions.
The inhibition of TBC1D10C can affect a variety of molecular pathways associated with the control of membrane dynamics, specifically targeting interactions that modulate cytoskeletal organization, cellular morphology, and the sorting of cargo within the endosomal system. These inhibitors provide researchers with a tool to dissect the regulatory networks associated with small GTPase signaling and the role of TBC1D10C in maintaining cellular homeostasis. By controlling the activity of GTPases, TBC1D10C inhibitors can also help in studying the molecular mechanisms involved in autophagy, cell migration, and intracellular signal transduction. The specificity of these inhibitors allows for detailed exploration of how TBC1D10C coordinates various signaling events within cells, aiding in the understanding of key biochemical processes that govern cell function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that by suppressing the mTOR pathway, can reduce the activity of proteins downstream of mTOR signaling, such as TBC1D10C. Since TBC1D10C may be involved in cellular processes that are regulated by mTOR, its functional activity can be reduced when mTOR signaling is diminished. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, and since PI3K is upstream of mTOR signaling, inhibition of PI3K by Wortmannin can lead to reduced mTOR activity. This would consequently inhibit the downstream signaling pathways and proteins that are regulated by mTOR, including TBC1D10C. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents the phosphorylation and activation of proteins in the PI3K/AKT/mTOR signaling pathway. The inhibition of this pathway can lead to decreased activity of downstream proteins such as TBC1D10C, assuming TBC1D10C's role is downstream of mTOR activation. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits the AKT pathway, which is involved in the regulation of mTOR and its downstream signaling components. Given that TBC1D10C might be a downstream effector of the mTOR pathway, blocking AKT can lead to reduced activation of mTOR and consequently, a decrease in functional activity of TBC1D10C. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor which, by blocking EGFR, can decrease activation of the downstream PI3K/AKT/mTOR pathway. Since this pathway is a key regulator of cell survival and proliferation processes in which TBC1D10C could be involved, inhibition by Erlotinib could reduce TBC1D10C activity indirectly. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib, a dual tyrosine kinase inhibitor targeting both EGFR and HER2, can impede the PI3K/AKT/mTOR signaling pathway. If TBC1D10C functions downstream of this pathway, its activity would be decreased as a result of Lapatinib's action. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF, among other kinases. By inhibiting RAF, the downstream signaling through the MEK/ERK pathway, which could converge on the mTOR pathway, is reduced. This reduction can lead to decreased activity of proteins like TBC1D10C, assuming they are regulated by mTOR signaling. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, which can reduce signaling through pathways like PI3K/AKT/mTOR. As a result, the functional activity of downstream proteins such as TBC1D10C can be inhibited if they are part of the cellular processes governed by these pathways. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an mTOR kinase inhibitor that directly inhibits both mTORC1 and mTORC2 complexes. The inhibition of these complexes can lead to a decrease in the activity of downstream proteins regulated by mTOR signaling, potentially including TBC1D10C. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that leads to cell cycle arrest. While it is not directly involved in the mTOR pathway, the resulting arrest in cell cycle progression can reduce the need for mTOR signaling, which may indirectly lead to decreased activity of proteins associated with this pathway, like TBC1D10C. | ||||||